SAN DIEGO, June 21 Orexigen® Therapeutics, Inc. (Nasdaq: OREX) a biopharmaceutical company focused on the treatment of obesity, today announced the schedule of its upcoming Contrave® (naltrexone sustained release (SR)/bupropion SR) and Empatic(TM) (zonisamide SR/bupropionSR) presentations taking place at the American Diabetes Association (ADA) 70th Scientific Sessions, June 25-29, 2010.
Advertisement
ADA: Orange County Convention Center (West Building), Orlando, FL.
About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company has filed an NDA with the FDA for its lead investigational product, Contrave®. The Company's second product, Empatic(TM), has completed Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches. Further information about the Company can be found at www.orexigen.com.
Advertisement
Friday, June 25: Oral Presentation Abstract: 56-OR Presenter: Priscilla Hollander, M.D., Baylor Medical Center, Dallas, TX Title: "COR-Diabetes: Naltrexone SR/Bupropion SR Combination Therapy Led to Significant and Sustained Weight Loss and Improved HbA1c in Overweight/Obese Subjects with Type 2 Diabetes" Time: 5:45 p.m. EST Location: Room 314 Oral Session: Obesity - Human Sunday, June 27: Poster Presentation Poster Presentation Abstract: 1851-P Abstract: 1848-P Presenter: Susan L. McElroy, Presenter: Steven R. Smith, M.D., M.D., Lindner Center of Pennington Biomedical Research HOPE, Mason, OH Center, Baton Rouge, LA. Title: "An Open-Label Study Evaluating the Naltrexone SR/BupropionSR Combination Title: "Naltrexone SR/BupropionSR Therapy in Overweight or Combination Therapy Reduces Total and Obese Subjects with Major Visceral Adiposity in Overweight and Depression" Obese Subjects in the COR-I Study" Time: 12:00 - 2:00 p.m. EST Time: 12:00 - 2:00 p.m. EST Location: Poster Hall Location: Poster Hall Category: 19-B Obesity - Human Category: 19-B Obesity - Human Guided Tour, Saturday, June Guided Tour, Monday, June 28th, 1:00 - 26th, 11:30a.m. -12:30 p.m. 2:00 p.m. Poster Presentation Published Abstract Only Abstract: 1841-P Abstract: 2633-PO Presenter: Alok, K. Gupta, M.D., Presenter: Ken Fujioka, M.D., Pennington Biomedical Research Scripps Clinic, Del Mar, CA Center, Baton Rouge, LA. Title: "A Phase 2B, 24-week Study Evaluating the Efficacy and Safety of Two Title: "Improved Glycemic Control and Doses of Zonisamide SR/ Weight Loss with Naltrexone SR/ BupropionSR Combination BupropionSR Combination Therapy in Therapy in Overweight and Overweight/Obese Subjects with Type Obese Subjects" 2 Diabetes" Time: 12:00 - 2:00 p.m. EST Category: 19-B Obesity - Human Location: Poster Hall Guided Tour, Monday, June 28th, 1:00 -2:00 p.m.
SOURCE Orexigen Therapeutics, Inc.
